Linear epitope mapping of humoral responses induced by vaccination with recombinant HIV-1 envelope protein gp160

Journal of Industrial Microbiology and Biotechnology

Volumn 19, Issue 1, 1997, Pages 58-65

  Loomis Price, L D ^a   Levi, M ^b   Burnett, P R ^c   Van Hamont, J E ^d   Shafer, R A ^e   Wahren, B ^b   Birx, D L ^d  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c US Army Dental Research Detachment   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e NASA GODDARD SPACE FLIGHT CENTER   (United States)

Author keywords

gp120; gp42; HIV antibodies; HIV vaccines; Pepscan; Statistical data analysis

Indexed keywords

ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PEPTIDE; VIRUS GLYCOPROTEIN;

ARTICLE; EPITOPE MAPPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; STATISTICAL MODEL; VACCINATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; EPITOPE MAPPING; HIV ENVELOPE PROTEIN GP160; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; RABBITS; VACCINATION; VACCINES, SYNTHETIC;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS;

EID: 0030696073     PISSN: 13675435     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jim.2900410     Document Type: Article

References (32)

1. Aaskov JG, HM Geysen and TJ Mason. 1989. Serologically defined linear epitopes in the envelope protein of dengue 2 (Jamaica strain 1409). Arch Virol 105: 209-221.
2. Birx DL, N Ketter and P Fast. 1996. HIV vaccine development: treatment and prevention. In: Clinical Immunology: Principles and Practice, Vol 1 (Rich RR, ed), pp 764-778, Mosby, St Louis, MO.
3. Carter JM. 1994. Epitope mapping of a protein using the Geysen (PEPSCAN) procedure. In: Methods in Molecular Biology, Vol 36: Peptide Analysis Protocols (Dunn BM and Pennington MW, eds), pp 207-223, Humana Press Inc, Totowa, NJ.
4. Carter JM, S VanAlbert, J Lee, J Lyon and C Deal. 1992. Shedding light on peptide synthesis. BioTechnology 10: 509-513.
5. Cason J. 1994. Strategies for mapping and imitating viral B-cell epitopes. J Virol Meth 49: 209-220.
6. Cassels FJ, CD Deal, RH Reid, DL Jarboe, JL Nauss, JM Carter and EC Boedeker. 1992. Analysis of Escherichia coli colonization factor antigen I linear B-cell epitopes, as determined by primate responses, following protein sequence verification. Infect Immun 60: 2174-2181.
7. Castric PA and CD Deal. 1994. Differentiation of Pseudomonas aeruginosa pili based on sequence and B-cell epitope analyses. Infect Immun 62: 371-376.
8. Coursaget P, G Lesage, P LeCann, V Mayelo and C Bourdil. 1991. Mapping of linear B-cell epitopes of hepatitis B surface antigen. Res Virol 142: 461-467.
9. Eldridge JH, JK Staas, JA Meulbroek, TR Tice and RM Gilley. 1991. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 59: 2978-2986.
10. Epping RJ, SD Goldstone, LT Ingram and JA Upcroft. 1988. An epitope recognized by inhibitory monoclonal antibodies that react with a 51 kilodalton merozoite surface antigen in Plasmodium falciparum. Mol Biochem Parasitol 28: 1-10.
11. Geysen HM, RH Meloen and SJ Barteling. 1984. Use of peptide synthesis to prove viral antigens for epitopes to a resolution of a single amino acid. Proc Natl Acad Sci USA 81: 3998-4002.
12. Geysen HM, SJ Rodda and TJ Mason. 1986. A priori delineation of a peptide which mimics a discontinuous antigenic determinant. Mol Immunol 23: 709-715.
13. Geysen HM, SJ Rodda, TJ Mason, G Tribbik and PG Schoofs. 1987. Strategies for epitope analysis using peptide synthesis. J Immun Meth 102: 259-274.
14. Goudsmit J, RH Meloen and R Brasseur. 1990. Map of sequential B-cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe. Intervirology 31: 327-338.
15. Johnson R. 1977. Elementary Statistics. Duxbury Press, North Scituate, MA.
16. Kaminski RW, L Loomis, M Levi, S Amselem, K Kersey, T VanCott, A Yogev, D Friedman, G Smith, B Wahren, R Redfield, D Birx and GH Lowell. 1995. HIV peptide and protein antibody responses elicited by immunization with rgp160 formulated with proteosomes, alum, and/or submicron emulsions. Vacc Res 4: 189-206.
17. Levi M, U Ruden, D Birx, L Loomis, R Redfield, K Lovgren, L Akerblom, E Sandstrom and B Wahren. 1993. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1. J Acquir Immune Defic Syndr 6: 855-864.
18. Loomis LD, CD Deal, KS Kersey, DS Burke, RR Redfield and DL Birx. 1995. Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160. J Acquir Immune Defic Syndr 10: 13-26.
19. Matthews R, JP Burnie and W Lee. 1991. The application of epitope mapping in the development of a new serological test for systemic candidosis. J Immunol Meth 143: 73-79.
20. Myers G, AB Rabson, SF Josephs, TF Smith and F Wong-Staal. 1995. Human retroviruses and AIDS: HIV Sequence Database. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
21. Palker TJ, TJ Mathews, ME Clark, GJ Ciancolo, RR Randall, AJ Langlois, GC White, B Safei, R Snyderman, DP Bolognesi and BF Haynes. 1987. A conserved epitope at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope. Proc Natl Acad Sci USA 84: 2479-2483.
22. Pincus SH, KG Messer, PL Nara, WA Blatner, G Colclough and M Reitz. 1994. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. J Clin Invest 93: 2505-2513.
23. Pincus SH, KG Messer, DH Schwartz, GK Lewis, BS Graham, WA Blattner and G Fisher. 1993. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J Clin Invest 91: 1987-1996.
24. Redfield R, D Birx, N Ketter, V Polonis, S Johnson, C Davis, G Smith, C Oster and D Burke. 1992. Vaccine therapy using rgp160 in early HIV infection. AIDS Res Hum Retrov 8: 1333.
25. Redfield RR, DL Birx, N Ketter, E Tramont, V Polonis, C Davis, JF Brundage, G Smith, S Johnson and A Fowler. 1991. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 324: 1677-1684.
26. Schnittman SM and AS Fauci. 1994. Human immunodeficiency virus and acquired immunodeficiency syndrome: an update. Adv Intern Med 39: 305-355.
27. Schoofs PG, HM Geysen, DC Jackson, LE Brown, X-L Tang and DO White. 1988. Epitopes of an influenza peptide recognized by antibody at single amino acid resolution. J Immunol 2: 611-616.
28. Valerio RM, AM Bray, RA Campbell, A DiPasquale, C Margellis, SJ Rodda, HM Geysen and NJ Maeji. 1993. Multipin peptide synthesis at the micromole scale using 2-hydroxyethyl methacrylate grafted polyethylene supports. Int J Peptide Protein Res 42: 1-9.
29. VanAlbert S, J Lee, J Lyons and JM Carter. 1991. Amino acid indexer for synthesis of Geysen peptides. US Patent #5 243 540.
30. Wallace GR, AE Ball, J MacFarlane, SH El Safi, MA Miles and JM Kelly. 1992. Mapping of a visceral Leishmaniasis-specific immunodominant B-cell epitope of Leishmania donovani Hsp70. Infect Immun 60: 2688-2693.
31. Wang J, S Steel, L Montagnier and P Sonigo. 1986. Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein. Proc Natl Acad Sci USA 83: 6159-6163.
32. Zhong G, RE Reid and RC Brunham. 1990. Mapping antigenic sites on the major outer membrane protein of Chlamydia trachomatis with synthetic peptides. Infect Immun 58: 1450-1455.